GSK believes Egypt is a key  emerging  market with a lot of untapped potential and yet to be fulfilled promises,hence the great emphasis and large investment placed by the GlaxoSmithKline plc into GSK Egypt placingit as the number one British investment in the pharmaceutical industry in the country and the market leaderwith a share of approximately 9%. The Company’s turnover is £115 million comprised of 56% GSK brands,29% locally acquired brands, 11% vaccines, and 4% licensors.

Reaching this prestigious spot was not an easy feat, but a long journey of hard work that started as far backas 1901 when Wellcome had its floating laboratory on the Nile. Constantly seeking to improve its abilities,expand its operations, and upgrade its facilities the Company went through a series of mergers andacquisitions, the latest in October 2008. Realizing that the coming years are ripe with challenges and aturbulent economy, GSK made the strategic decision of taking the lead and be a step ahead of all othersby the GlaxoSmithKline plc acquisition of the mature Egyptian brands of Bristol Myers Squibb and theirstate of the art facility in Giza. In so doing, the Company expanded its pharmaceutical portfolio enteringfour new therapeutic areas and obtaining twenty medicines that are well established effective leading brandsin their own right at affordable prices.

Now, GSK Egypt possesses and provides medication for nine out of the ten disease areas in Egypt, targetingailments that range from diabetes, asthma, cancer, liver viruses, and gastrointestinal problems, to infectionsallergies, coughs and colds, vitamin and nutritional deficiencies,anti-depressants and cardiovascular disorders, and many more.

Improving the quality of human life is a GSK global quest andas such it places the best interest of the patient at the front andcenter of its priorities, driving all its operations. Being thenumber one in market share is not what matters to GSK Egypt;being the number one in providing the best service to patients,certainly is.

To us, best service translates into: best quality, best technology,best possible price, the best match to the needs of the localmarket, and being the partner of choice to all our stakeholders.

The Company, with the last Bristol Myers acquisition, has twomanufacturing sites, one in Cairo and the other in Giza thatare the largest in the Middle East and North Africa region,producing 141 million units per year. The production covers awide profile of products ranging from tablets, capsules, liquids,topical, cephalosporin, soft gelatine and sterile. While themajority of the manufactured products is consumed locally, atleast 15% of the total production is exported to 29 internationalmarkets, led by Romania and Nigeria, with total exports at LE105 million. The Company is currently the number two exporterin the field, and has bold plans and strategies that will take itto the number one position, which will be made even morereachable with the latest acquisition that will enable the Companyto produce and export at double the current pace.

In the pharmaceutical industry, it is vital to have a strong pipeline– to have enough medicines in development to ensure therewill always be new and improved treatments to face the evermore challenging diseases. Using the most modern technology,GSK scientists strive to understand the complex mechanismsthat cause disease, helping them to develop medicines thatare more effective and better tolerated. GSK is mainly aresearch based company, spending £8 million on research anddevelopment every single day. It should be noted that it costsover £500 million and takes an average of 12 years of dedicatedand diligent work to produce one new medicine.

GSK Egypt is proud to boast receipt of a number of certificates and awards recognizing superior performance, compliance with

environmental standards and requirements, and the provision of a safe and healthy work environment.